Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF ANTAGONISTS AT THE HUMAN RECOMBINANT P2X(7) RECEPTOR
Autore:
CHESSELL IP; MICHEL AD; HUMPHREY PPA;
Indirizzi:
UNIV CAMBRIDGE,DEPT PHARMACOL,GLAXO INST APPL PHARMACOL,TENNIS COURT RD CAMBRIDGE CB2 1QJ ENGLAND
Titolo Testata:
British Journal of Pharmacology
fascicolo: 6, volume: 124, anno: 1998,
pagine: 1314 - 1320
SICI:
0007-1188(1998)124:6<1314:EOAATH>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PURINERGIC RECEPTORS; HUMAN-LYMPHOCYTES; PATCH-CLAMP; ATP; INHIBITION; MACROPHAGES; CHANNELS; CELLS;
Keywords:
HUMAN P2X(7) RECEPTORS; SURAMIN; ATP ANTAGONIST; PORE; KN-62;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
I.P. Chessell et al., "EFFECTS OF ANTAGONISTS AT THE HUMAN RECOMBINANT P2X(7) RECEPTOR", British Journal of Pharmacology, 124(6), 1998, pp. 1314-1320

Abstract

1 We have used whole-cell patch clamping methods to examine the properties of the recombinant human P2X(7) (P2Z) receptor stably expressed in HEK-293 cells.2 In an extracellular solution with lowered concentrations of divalent cations (zero Mg2+ and 0.5 mM Ca2+), both ATP and the nucleotide analogue: 2'- and 3'-O-(4-benzoylbenzoyl)-adenosine 5'-triphosphate (Bz-ATP) evoked concentration-dependent whole-cell inward currents with maxima of 4658+/-671 and 5385+/-990 pA, respectively, at a holding potential of -90 mV. Current-voltage relationships determined using 100 mu M Bz-ATP reversed at -2.7+/-3.1 mV, and did not displaysignificant rectification. 3 Repeated applications of 300 mu M Bz-ATPproduced inward currents with similar rise-times (approx. 450 ms, 5-95% current development) but with progressively slower 95-5% decay times, with the eighth application of this agonist yielding a decay time of 197% of the first application. 4 Concentration-effect curves to ATP and Bz-ATP produced estimated EC50 values of 780 and 52.4 mu M, respectively. Consecutive concentration-effect curves to Bz-ATP produced curves with similar maxima and EC50 values. 5 The non-selective P2 antagonists, pyridoxal-phosphate-6-azophenyl-, 2',4'-disulphonic acid (PPADS) and suramin, both produced concentration-dependent increases in maximal inward currents to Bz-ATP, with IC50 concentrations of approximately 1 mu M and 70 mu M, respectively. The profile of antagonism produced by PPADS was not that of a competitive antagonist. 6 The isoquinolene derivatives esulphonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine (KN-62) and calmidazolium both produced antagonism which was not competitive, with IC50 concentrations of approximately 15 and 100 nM, respectively. HMA (5-(N,N-hexamethylene)- amiloride) was also an effective antagonist at a concentration of 10 mu M. The group IIb metal, copper, alsodisplayed antagonist properties at the human P2X(7) receptor, reducing the maximum response to Bz-ATP by about 50% at a concentration of 1 mu M. 7 These data demonstrate that the human recombinant P2X(7) receptor displays functional behaviour which is similar to the recombinant rat P2X(7) receptor, but has a distinct pharmacological profile with respect to agonist and antagonist sensitivity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 18:43:49